ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > No Trades Today - Oc4 4

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Oct 04, 2022 12:25pm

101 Views

Post# 35004381

RE:No Trades Today - Oc4 4

Ask someone that has Level 2 trading they can see whats happening on the asks and bids .. there may be a huge block set up around 9 $ and not enough available at the lower levels to force a drop in the share price ..

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China